Intravesical drug delivery strategies for NMIBC

A permanent J code helps standardize billing and clarifies expected payment levels, often embedding reimbursement terms into payer contracts.

Rubenstein emphasizes the importance of strong clinical documentation and preparation by billing teams.

“Once we actually get a J code for a medication, it really solidifies the amount of reimbursement that's going to occur,” says Jonathan Rubenstein, MD.

Christopher M. Pieczonka, MD, discusses practical strategies to optimize tolerability and minimize early discontinuation with indwelling intravesical drug-releasing systems for bladder cancer.

David Morris, MD, FACS, discusses expert panel recommendations on intravesical drug-releasing systems in bladder cancer, highlighting early drug release dynamics, tolerability, and optimizing patient comfort.

David Morris, MD, FACS, highlights key strategies for counseling patients receiving the gemcitabine intravesical system as well as considerations for maintaining patients on therapy long enough to achieve meaningful clinical benefit.

Proactive adverse event counseling and a specific hydration protocol are the primary tools for supporting patient retention through the gemcitabine intravesical system's (Inlexzo) extended treatment course, according to Mobley.

Elizabeth Mobley, MD, shares practical tips for counseling patients and managing adverse events during treatment with the gemcitabine intravesical system.

Dose interruption rather than discontinuation addresses most gemcitabine intravesical system (Inlexzo) adverse events, with designated champions supporting consistent patient management, according to Elizabeth Mobley, MD.